| Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia H Kantarjian, NP Shah, A Hochhaus, J Cortes, S Shah, M Ayala, ... New England Journal of Medicine 362 (24), 2260-2270, 2010 | 2039 | 2010 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1322 | 2013 |
| Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, ... Journal of Clinical Oncology 34 (20), 2333-2340, 2016 | 1068 | 2016 |
| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 684 | 2012 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 597 | 2018 |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ... Journal of Clinical Oncology 36 (3), 231-237, 2018 | 548 | 2018 |
| Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) E Jabbour, HM Kantarjian, G Saglio, JL Steegmann, NP Shah, C Boqué, ... Blood, The Journal of the American Society of Hematology 123 (4), 494-500, 2014 | 490 | 2014 |
| Regulation of myeloid leukaemia by the cell-fate determinant Musashi T Ito, HY Kwon, B Zimdahl, KL Congdon, J Blum, WE Lento, C Zhao, ... Nature 466 (7307), 765-768, 2010 | 415 | 2010 |
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 373 | 2014 |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ... The Lancet Oncology 17 (5), 612-621, 2016 | 286 | 2016 |
| Resistance to imatinib mesylate in chronic myeloid leukaemia JV Melo, C Chuah Cancer letters 249 (2), 121-132, 2007 | 212 | 2007 |
| Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah, N Nanda, ... Blood, The Journal of the American Society of Hematology 120 (13), 2573-2580, 2012 | 187 | 2012 |
| Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial J Cortes, J Apperley, E Lomaia, B Moiraghi, M Undurraga Sutton, ... Blood, The Journal of the American Society of Hematology 138 (21), 2042-2050, 2021 | 166 | 2021 |
| Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function S Lim, TY Saw, M Zhang, MR Janes, K Nacro, J Hill, AQ Lim, CT Chang, ... Proceedings of the National Academy of Sciences 110 (25), E2298-E2307, 2013 | 165 | 2013 |
| Chronic myeloid leukemia in Asia WY Au, PB Caguioa, C Chuah, SC Hsu, S Jootar, DW Kim, IY Kweon, ... International journal of hematology 89, 14-23, 2009 | 161 | 2009 |
| Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation FE Nicolini, MJ Mauro, G Martinelli, DW Kim, S Soverini, MC Müller, ... Blood, The Journal of the American Society of Hematology 114 (26), 5271-5278, 2009 | 150 | 2009 |
| Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia S Branford, DDH Kim, JF Apperley, CA Eide, S Mustjoki, ST Ong, ... Leukemia 33 (8), 1835-1850, 2019 | 143 | 2019 |
| Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia B Zimdahl, T Ito, A Blevins, J Bajaj, T Konuma, J Weeks, CS Koechlein, ... Nature genetics 46 (3), 245-252, 2014 | 127 | 2014 |
| Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation FE Nicolini, GW Basak, DW Kim, E Olavarria, J Pinilla‐Ibarz, JF Apperley, ... Cancer 123 (15), 2875-2880, 2017 | 125 | 2017 |
| CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia J Bajaj, T Konuma, NK Lytle, HY Kwon, JN Ablack, JM Cantor, D Rizzieri, ... Cancer cell 30 (5), 792-805, 2016 | 113 | 2016 |
